EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial

Anant Ramaswamy iD, Prabhat Bhargava iD, Sujay Srinivas iD, Akhil Kapoor iD, Bal Krishna Mishra, Anuj Gupta, Sarika Mandavkar, Sadhana Kannan, Deepali Chaugule, Rajshree Patil, Manali Parulekar, Chaitali Nashikkar und 7 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.02420 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Anant Ramaswamy und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. Hauptthemen laut MEDLINE: Bevacizumab, Erlotinib Hydrochloride, Gallbladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with chemotherapy-responsive advanced biliary tract cancers (BTCs) are usually observed after 6 months of gemcitabine-based therapy. There is limited prospective evidence for maintenance strategies after chemotherapy. METHODS This investigator-initiated, open-label, randomized, integrated phase II-III study enrolled adult patients with advanced BTC from two cancer centers in India. Patients with histologically confirmed advanced biliary tract adenocarcinoma who had at least disease stabilization after 6 months of gemcitabine-based chemotherapy were randomly assigned (1:1) to either active surveillance or switch maintenance, which was a combination of bevacizumab 5 mg/kg intravenous once every 21 days plus erlotinib 100 mg once daily. Both arms were continued until disease progression, unacceptable toxicity, or patient decision to withdraw. The primary end point of the phase II component of the trial was investigator-evaluated progression-free survival. This trial is registered with Clinical Trials Registry of India (CTRI/2019/05/019323I). RESULTS From May 2021 to November 2022, 98 patients were randomly assigned to active surveillance (n = 49) or bevacizumab-erlotinib (n = 49). A majority of patients had gallbladder cancer (80%). The median follow-up was 13.4 months. The median progression-free survival was 3.1 months (95% CI, 2.47 to 3.64) in the active surveillance group versus 5.3 months (95% CI, 3.53 to 7.04) in the bevacizumab-erlotinib group (hazard ratio, 0.51 [95% CI, 0.33 to 0·74]; P = .0013). The most common grade 3 class-specific adverse events associated with bevacizumab-erlotinib were acneiform rash 1 (2%) and oral stomatitis 1 (2%) with erlotinib and bleeding 1 (2%) with bevacizumab. CONCLUSION The combination of bevacizumab and erlotinib as switch maintenance improves progression-free survival with an acceptable safety profile compared with active surveillance in patients with advanced BTCs in this phase II study. The trial moves on to the phase III component to evaluate improvement in overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabErlotinib HydrochlorideGallbladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCholangiocarcinomaGemcitabineHumansMaleFemaleMiddle AgedAgedAdultDeoxycytidineProgression-Free SurvivalBile Duct Neoplasms

Substanzen

BevacizumabErlotinib HydrochlorideGemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India.
  • Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

ORCID-Profile: Anant Ramaswamy, Prabhat Bhargava, Sujay Srinivas, Akhil Kapoor, Rajiv Kumar Kaushal, Vikas Ostwal

Zitieren

APA

Ramaswamy, A., Bhargava, P., Srinivas, S., Kapoor, A., Mishra, B. K., Gupta, A., Mandavkar, S., Kannan, S., Chaugule, D., Patil, R., Parulekar, M., Nashikkar, C., Ankathi, S. K., Kaushal, R. K., Naughane, D., Daddi, A., Mer, N., Shetty, N., & Ostwal, V. (2024). Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02420

Vancouver

Ramaswamy A, Bhargava P, Srinivas S, Kapoor A, Mishra BK, Gupta A, et al. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02420

BibTeX
@article{Ramaswamy2024,
  author = {Ramaswamy, Anant and Bhargava, Prabhat and Srinivas, Sujay and Kapoor, Akhil and Mishra, Bal Krishna and Gupta, Anuj and Mandavkar, Sarika and Kannan, Sadhana and Chaugule, Deepali and Patil, Rajshree and Parulekar, Manali and Nashikkar, Chaitali and Ankathi, Suman Kumar and Kaushal, Rajiv Kumar and Naughane, Deepali and Daddi, Anuprita and Mer, Neha and Shetty, Nitin and Ostwal, Vikas},
  title = {Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02420}
}
Kostenlos starten →